In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine. (more…)
In a new article on PM360, Precision for Value executive vice president Bruce Leavitt provides step-by-step guidance for drug makers who find their product on one of the recently released formulary exclusion lists. (more…)
In the latest edition of Managed Healthcare Executive, Jeremy Schafer, Precision for Value senior vice president, director of payer access solutions, discusses value in oncology and explains how payers are using value frameworks in their drug management process. (more…)
In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. (more…)
In a new commentary for PharmExec.com, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. (more…)
In the current supplemental issue of Journal of Managed Care & Specialty Pharmacy (JMCP), Precision’s Jeremy Schafer, Dominic Galante, and Jason Shafrin share results of a recent survey of payers discerning payers’ use of value tools in healthcare decision-making.
Precision for Value’s Larry Blandford offers a new commentary in STAT First Opinion, insisting that payers and the pharmaceutical industry come together to develop a value-based drug reimbursement system. He suggests taking a page from the playbook developed for electronic prescribing as the key to moving forward.
Jeremy Schafer and Maureen Hennessey promote antimicrobial stewardship in a new commentary for Managed Healthcare Executive, offering 4 specific steps: rewarding antimicrobial stewardship, leveraging quality scores, implementing appropriate controls, and the establishment of patient education campaigns.
Precision for Value’s Kelly Wilder is interviewed by PharmaVoice and provides her perspectives on the payer landscape, the definition of value, and best practices for pharmaceutical companies.
Denver (3-30-17)—The oncology landscape is rapidly evolving. A Pharmaceutical Research and Manufacturers of America report noted that 836 oncology drugs and vaccines are in the pipeline, 123 of which are for lung cancer, and 80% of pipeline agents are potential first-in-class therapies. Because of this, existing treatment paradigms are regularly upset. In addition, oncology costs continue to grow, with a reported $105 billion spent globally in 2015 and projected to rise 7.5% to 11.5% annually through 2020. In response, payers are using clinical pathways, preferred product and exclusion lists, and value assessment framework tools for better management of costs and care. Value-based risk sharing models among payers, providers and pharmaceutical manufacturers are also evolving.